How has MoonLake Immunotherapeutics - Ordinary Shares - Class A performed historically?

The MoonLake Immunotherapeutics - Ordinary Shares - Class A is currently trading up 1.16% on an intraday basis in the past week the index fell -1.52%. The index has been up 9.71% in the past quarter and rose 10.15% in the past year. You can view this in the overview section.

What is MoonLake Immunotherapeutics - Ordinary Shares - Class A Annual Net Profit?

MoonLake Immunotherapeutics - Ordinary Shares - Class A Annual Net Profit fell 230.31% in the last year to $118.94 M. Its sector's average net profit growth for the last fiscal year was -14.04%.

What is MoonLake Immunotherapeutics - Ordinary Shares - Class A Price to Earning Ratio?

MoonLake Immunotherapeutics - Ordinary Shares - Class A Price to Earning Ratio is -19.02, which is negative.

What is MoonLake Immunotherapeutics - Ordinary Shares - Class A Quarterly Net profit?

MoonLake Immunotherapeutics - Ordinary Shares - Class A Quarterly Net profit fell 192.14% YoY to $39.94 M. Its sector's average net profit growth YoY for the quarter was -236.05%.

What is MoonLake Immunotherapeutics - Ordinary Shares - Class A Debt to Equity Ratio?

MoonLake Immunotherapeutics - Ordinary Shares - Class A Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is MoonLake Immunotherapeutics - Ordinary Shares - Class A Return on Equity(ROE)?

MoonLake Immunotherapeutics - Ordinary Shares - Class A Return on Equity(ROE) for the last financial year was -25.24%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is MoonLake Immunotherapeutics - Ordinary Shares - Class A Mutual Fund Holding?

MoonLake Immunotherapeutics - Ordinary Shares - Class A Mutual Fund Holding decreased by 1.62% in the last quarter to 34.75.

What is MoonLake Immunotherapeutics - Ordinary Shares - Class A Institutional Holding?

MoonLake Immunotherapeutics - Ordinary Shares - Class A Institutional Holding decreased by 4.47% in the last quarter to 95.53.

MARKETS
SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
INDUSTRY : MAJOR PHARMACEUTICALS
MOONLAKE IMMUNOTHERAPEUTICS - ORDINARY SHARES - CLASS A

MoonLake Immunotherapeutics - Ordinary Shares - Class A XNAS: MLTX

MoonLake Immunotherapeutics - Ordinary Shares - Class A Live Share Price Today, Share Analysis and Chart

Name: MoonLake Immunotherapeutics - Ordinary Shares - Class A: Is Infosys Ltd. worth buying?
Item: MoonLake Immunotherapeutics - Ordinary Shares - Class A
Rating: 1.16708325
Author: Trendlyne DVM scores

about

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibit...

43.50 0.50 (1.16%)

38.45% Gain from 52W Low

414.8K

XNAS Volume

XNAS 18 Jun, 2025 5:30 PM (EDT)

Not Eligible

Expensive Valuation

3.3 / 100

Technically Neutral

43.4 / 100

No estimates available

MoonLake Immunotherapeutic... Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

MoonLake Immunotherapeutics - Ordinary Shares - Class A Live Share Price Today, Share Analysis and Chart

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibit...

38.45% Gain from 52W Low

SWOT Analysis

MoonLake Immunotherapeutic... Live Price Chart

MoonLake Immunotherapeutics - Ordinary Shares - Class A FAQ

How is MoonLake Immunotherapeutics - Ordinary Shares - Class A today?

MoonLake Immunotherapeutics - Ordinary Shares - Class A today is trading in the green, and is up by 1.16% at 43.50.

How has MoonLake Immunotherapeutics - Ordinary Shares - Class A performed historically?

MoonLake Immunotherapeutics - Ordinary Shares - Class A is currently trading up 1.16% on an intraday basis. In the past week the stock fell -1.52%. stock has been up 9.71% in the past quarter and rose 10.15% in the past year. You can view this in the overview section.